2-Acylhydrazino-5-arylpyrrole derivatives: Synthesis and antifungal activity evaluation

European Journal of Medicinal Chemistry

Volumn 44, Issue 3, 2009, Pages 1288-1295

  Onnis, Valentina ^a   De Logu, Alessandro ^a   Cocco, Maria T ^a   Fadda, Roberta ^a   Meleddu, Rita ^a   Congiu, Cenzo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

2 Acylhydrazino 5 arylpyrroles; Antifungal activity; Candidae; Cytotoxic activity

Indexed keywords

2 (2 ACETYLHYDRAZINYL) 5 (4 METHOXYPHENYL) 1H PYRROLE 3 CARBONITRILE; 2 (2 ACETYLHYDRAZINYL) 5 PHENYL 1H PYRROLE 3 CARBONITRILE; 2 (2 ETHOXYCARBONYLHYDRAZINYL) 5 (4 METHOXYPHENYL) 1H PYRROLE 3 CARBONITRILE; 2 (2 ETHOXYCARBONYLHYDRAZINYL) 5 PHENYL 1H PYRROLE 3 CARBONITRILE; 2 [2 (2 METHOXYACETYL)HYDRAZINYL] 5 (4 METHOXYPHENYL) 1H PYRROLE 3 CARBONITRILE; 2 [2 (2 METHOXYACETYL)HYDRAZINYL] 5 PHENYL 1H PYRROLE 3 CARBONITRILE; 2 [2 (3 METHOXYPROPANOYL)HYDRAZINYL] 5 PHENYL 1H PYRROLE 3 CARBONITRILE; 2 ACYLHYDRAZINO 5 ARYLPYRROLE DERIVATIVE; 5 (4 METHOXYPHENYL) 2 (2 ISOBUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBONITRILE; 5 (4 METHOXYPHENYL) 2 (2 PROPANOYLHYDRAZINYL) 1H PYRROLE 3 CARBONITRILE; 5 PHENYL 2 (2 PROPANOYLHYDRAZINYL) 1H PYRROLE 3 CARBONITRILE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ETHYL 2 (2 BUTYRYLHYDRAZINYL) 5 PHENYL 1H PYRROLE 3 CARBOXYLATE; ETHYL 2 (2 ISOBUTYRYLHYDRAZINYL) 5 PHENYL 1H PYRROLE 3 CARBOXYLATE; ETHYL 2 [2 [2 (4-METHOXYPHENYL)ACETYL]HYDRAZINYL] 5 PHENYL 1H PYRROLE 3 CARBOXYLATE; ETHYL 2[2 (3 METHOXYPROPANOYL)HYDRAZINYL] 5 PHENYL 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 CHLOROPHENYL) 2 (2 BUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 CHLOROPHENYL) 2 (2 ISOBUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 CHLOROPHENYL) 2 [2 [2 (4 METHOXYPHENYL)ACETYL]HYDRAZINYL] 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 M0ETHOXYPHENYL) 2 [2 (3 METHOXYPROPANOYL)HYDRAZINYL] 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 METHOXYPHENYL) 2 (2 BUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 METHOXYPHENYL) 2 (2 ISOBUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 METHOXYPHENYL) 2 (2 PROPANOYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 METHYLPHENYL) 2 (2 BUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 METHYLPHENYL) 2 (2 ISOBUTYRYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 (4 METHYLPHENYL) 2 [2 [2 (4-METHOXYPHENYL)ACETYL]HYDRAZINYL] 1H PYRROLE 3 CARBOXYLATE; ETHYL 5 PHENYL 2 (2 PROPANOYLHYDRAZINYL) 1H PYRROLE 3 CARBOXYLATE; FLUCONAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANDIDA ALBICANS; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGAL STRAIN; HUMAN; HUMAN CELL; LUNG CANCER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; CANDIDA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; PYRROLES; SPECIES SPECIFICITY;

EID: 60549105829     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.08.003     Document Type: Article

References (28)

1. Brown J.M. Curr. Opin. Infect. Dis. 17 (2004) 347-352
2. Garber G. Drugs 61 (2001) 1-12
3. Walsh T.J., and Groll A.H. Transpl. Infect. Dis. 1 (1999) 247-261
4. Anaissie E. Clin. Infect. Dis. 14 (1992) S43-S53
5. Eggimann P., Garbino J., and Pittet D. Lancet Infect. Dis. 3 (2003) 685-702
6. Ampel N.M. Emerg. Infect. Dis. 2 (1996) 109-116
7. Pfaller M.A. Clin. Infect. Dis. 19 Suppl. 1 (1994) S8-S13
8. Powderly W.G., Kobayashi G.S., Herzig G.P., and Medoff G. Am. J. Med. 84 (1988) 826
9. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N., Doern G.V., Brandt M.E., and Hajjeh R.A. Diagn. Microbiol. Infect. Dis. 33 (1999) 217-222
10. Fanos V., and Cataldi L. J. Chemother. 12 (2000) 463-470
11. Sheehan D.J., Hitchcock C.A., and Sibley C.M. Clin. Microbiol. Rev. 12 (1999) 40-79
12. Deray G. J. Antimicrob. Chemother. 49 (2002) 37-41
13. Dupont B. J. Antimicrob. Chemother. 49 (2002) 31-36
14. Baddley J.W., and Moser S.A. Clin. Lab. Med. 24 (2004) 721-735
15. Ghannoum M.A., and Rice L.B. Clin. Microbiol. Rev. 12 (1999) 501-517
16. Perfect J.R. Oncology (Williston Park) 18 (2004) 15-22
17. Krcmery Jr. V.C. Med. Princ. Pract. 14 (2005) 125-135
18. Sanglard D., and Odds F.C. Lancet Infect. Dis. 2 (2002) 73-85
19. Marichal P. Curr. Opin. Anti-Infect. Invest. Drugs 1 (1999) 318
20. Jana C., and Julius S. Int. J. Antimicrob. Agents 27 (2006) 403
21. Cocco M.T., Congiu C., Maccioni A., Schivo M.L., and Palmieri G. Farmaco XLIII (1988) 319-331
22. Cocco M.T., Congiu C., Onnis V., and Maccioni A. J. Heterocycl. Chem. 28 (1991) 797-800
23. Cocco M.T., Congiu C., and Onnis V. Trends of Heterocyclic Chemistry, Research Trends (1995), Council of Scientific Informations pp. 13-23
24. Bernard A.M., Cocco M.T., Congiu C., Onnis V., and Piras P.P. J. Heterocycl. Chem. 33 (1996) 1771-1773
25. National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A (1997), NCCLS, Villanova, PA
26. Monks A., Scudiero D.A., Johnson G.S., Paull K.D., and Sausville E.A. Anticancer Drug Des. 12 (1997) 533
27. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K.D., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., and Boyd M. J. Natl. Cancer Inst. 83 (1991) 757-766
28. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornance Jr. A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., and Paull K.D. Science 275 (1997) 343-349